• Regulators are now mulling the results of the late-stage trial

Article Summaries:

  • A late‑stage clinical trial of a psychedelic‑based therapy for depression has shown promising results, with patients reporting significant symptom improvement and a favorable safety profile. The study, which enrolled several hundred participants across multiple sites, demonstrated that the drug outperformed placebo in reducing depressive scores and maintained benefits over a 12‑week follow‑up period. These findings have prompted regulatory authorities to begin a formal review of the data, as they consider whether to grant approval for the treatment. The trial’s outcomes could influence future approval pathways for psychedelic medicines targeting mood disorders.

Sources: